INO
Inovio Pharmaceuticals, Inc. NASDAQ Listed Dec 8, 1998$1.13
After hrs
$1.14
+0.84%
Mkt Cap $529.8M
52w Low $1.05
4.4% of range
52w High $2.87
50d MA $1.20
200d MA $1.77
P/E (TTM)
-0.7x
EV/EBITDA
—
P/B
22.0x
Debt/Equity
0.4x
ROE
-352.5%
P/FCF
-6.0x
RSI (14)
35.70
ATR (14)
$0.06
Beta
1.70
50d MA
$1.20
200d MA
$1.77
Avg Volume
2.3M
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
660 West Germantown Pike · Plymouth Meeting, PA 19462 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.37 | 0.31 | +183.8% | 1.68 | +2.4% | -1.2% | -1.8% | +3.1% | -1.2% | -0.6% | — |
| Nov 10, 2025 | AMC | -0.51 | -0.44 | +13.7% | 2.15 | -7.0% | -7.0% | -2.0% | -0.5% | +5.1% | -3.4% | — |
| Aug 12, 2025 | AMC | -0.63 | -0.61 | +3.2% | 1.49 | +0.7% | +14.1% | -4.7% | +14.8% | +2.2% | +2.1% | — |
| May 13, 2025 | AMC | -0.74 | -0.51 | +31.1% | 1.92 | +0.0% | -2.1% | +3.7% | +5.1% | +1.0% | +2.9% | — |
| Mar 18, 2025 | AMC | -0.87 | -0.69 | +20.7% | 2.10 | -0.5% | -6.7% | -1.0% | -1.0% | -2.1% | -3.7% | — |
| Nov 14, 2024 | AMC | -1.20 | -0.89 | +25.8% | 4.77 | +2.5% | -10.7% | -4.2% | -1.2% | -1.5% | +2.3% | — |
| Aug 8, 2024 | AMC | -1.15 | -1.19 | -3.5% | 8.71 | -2.4% | -3.1% | -1.4% | -5.2% | -0.9% | -0.3% | — |
| May 13, 2024 | AMC | -1.08 | -1.31 | -21.3% | 11.36 | +4.3% | +0.5% | +14.4% | -2.1% | -6.2% | -7.4% | — |
| Mar 6, 2024 | AMC | -1.27 | -1.12 | +11.8% | 9.87 | -2.2% | -8.5% | +12.7% | +18.3% | -4.4% | -2.3% | — |
| Nov 9, 2023 | AMC | -1.56 | -1.08 | +30.8% | 4.32 | +2.8% | -2.8% | +0.0% | +8.6% | +0.0% | +7.9% | — |
| Aug 9, 2023 | AMC | -1.68 | -1.56 | +7.1% | 4.80 | +2.5% | +15.0% | -2.2% | +2.2% | -2.2% | -2.2% | — |
| May 10, 2023 | AMC | -1.68 | -1.92 | -14.3% | 9.72 | +0.0% | -3.7% | -6.4% | +5.5% | -9.1% | +2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.95 | $1.98 | +1.5% | +5.1% | -3.4% | -4.5% | -5.8% | -2.8% |
| Aug 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.70 | $1.67 | -1.8% | -4.7% | +14.8% | +2.2% | +2.1% | -4.6% |
| May 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.92 | $1.92 | +0.0% | -2.1% | +3.7% | +5.1% | +1.0% | +2.9% |
| May 14 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $1.92 | $1.92 | +0.0% | -2.1% | +3.7% | +5.1% | +1.0% | +2.9% |
| Mar 19 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $2.10 | $2.09 | -0.5% | -6.7% | -1.0% | -1.0% | -2.1% | -3.7% |
| Mar 19 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $2.10 | $2.09 | -0.5% | -6.7% | -1.0% | -1.0% | -2.1% | -3.7% |
| Jan 13 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.98 | $1.94 | -2.0% | -4.0% | -1.6% | -0.5% | +2.7% | +8.9% |
| Jan 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.09 | $2.03 | -2.9% | -5.3% | -4.0% | -1.6% | -0.5% | +2.7% |
| Nov 18 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.26 | $4.16 | -2.3% | -4.2% | -1.2% | -1.5% | +2.3% | +0.2% |
| Nov 18 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $4.26 | $4.16 | -2.3% | -4.2% | -1.2% | -1.5% | +2.3% | +0.2% |
| Nov 15 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $4.77 | $4.89 | +2.5% | -10.7% | -4.2% | -1.2% | -1.5% | +2.3% |
| Aug 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.44 | $8.40 | -0.5% | -1.4% | -5.2% | -0.9% | -0.3% | +0.4% |
| Aug 9 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $8.71 | $8.50 | -2.4% | -3.1% | -1.4% | -5.2% | -0.9% | -0.3% |
| Jul 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $11.31 | $11.43 | +1.1% | -2.2% | +0.6% | -0.4% | -6.4% | -3.0% |
| Mar 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $9.03 | $9.00 | -0.3% | +12.7% | +18.3% | -4.4% | -2.3% | -3.9% |
| Mar 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $9.87 | $9.65 | -2.2% | -8.5% | +12.7% | +18.3% | -4.4% | -2.3% |
| Jan 25 | Oppenheimer | Upgrade | Perform → Outperform | — | $6.93 | $6.92 | -0.1% | -2.0% | -9.4% | +1.5% | -6.2% | -7.9% |
| May 11 | RBC Capital | Maintains | Sector Perform → Perform | — | $9.72 | $9.72 | +0.0% | -3.7% | -6.4% | +5.5% | -9.1% | +2.9% |
| May 10 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $10.08 | $9.96 | -1.2% | -3.6% | -3.7% | -6.4% | +5.5% | -9.1% |
| Mar 1 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $15.12 | $15.24 | +0.8% | -1.6% | +4.8% | +1.5% | -8.3% | -4.1% |
| Nov 8 | Maxim Group | Downgrade | Buy → Hold | — | $25.80 | $26.04 | +0.9% | -0.5% | +1.9% | +9.2% | -1.3% | +2.6% |
| Oct 31 | BofA Securities | Downgrade | Neutral → Underperform | — | $26.52 | $26.28 | -0.9% | -2.3% | -1.9% | +0.5% | +0.5% | -1.4% |
| Aug 9 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $28.32 | $26.88 | -5.1% | -11.0% | +23.8% | -5.4% | +6.9% | +6.1% |
| May 10 | Oppenheimer | Downgrade | Outperform → Perform | — | $28.44 | $29.40 | +3.4% | +5.1% | -27.3% | +3.9% | +5.9% | -5.0% |
| Mar 1 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $38.88 | $39.24 | +0.9% | +0.0% | -5.9% | +2.0% | +0.0% | +1.6% |
| Jan 20 | BofA Securities | Upgrade | Underperform → Neutral | — | $50.28 | $50.64 | +0.7% | -2.1% | -4.4% | +0.0% | +3.1% | -2.5% |
| Oct 31 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | — | — | — | — | — | — | — | — |
| Sep 9 | BofA Securities | Downgrade | Neutral → Underperform | — | $99.24 | $99.24 | +0.0% | +1.6% | -5.4% | -2.0% | -3.3% | +0.5% |
| Jun 24 | Jefferies | Maintains | Hold → Hold | — | $104.28 | $105.60 | +1.3% | +2.3% | +3.8% | +2.4% | +0.1% | -2.0% |
| Mar 23 | BofA Securities | Maintains | Neutral → Neutral | — | $123.84 | $123.00 | -0.7% | -7.8% | -5.6% | +0.9% | -0.3% | +0.1% |
| Feb 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $156.00 | $185.04 | +18.6% | +9.4% | -3.1% | +11.5% | -9.1% | -0.9% |
| Nov 16 | Roth Capital | Downgrade | Neutral → Sell | — | $134.64 | $150.72 | +11.9% | +14.5% | -8.9% | -5.6% | -0.2% | -4.4% |
| Nov 9 | Roth Capital | Upgrade | Sell → Neutral | — | $126.36 | $116.52 | -7.8% | -19.3% | +35.4% | -6.9% | +6.0% | -1.2% |
| Sep 27 | Maxim Group | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Sep 27 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | — | — | — | — | — | — | — | — |
| Jun 30 | Maxim Group | Downgrade | Buy → Hold | — | $380.28 | $324.48 | -14.7% | -15.0% | -26.8% | +8.7% | -2.4% | +15.1% |
| Jun 28 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Jun 25 | Stifel | Downgrade | Buy → Hold | — | $286.44 | $309.48 | +8.0% | +30.9% | -4.1% | +5.7% | -15.0% | -26.8% |
| Jun 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $286.44 | $309.48 | +8.0% | +30.9% | -4.1% | +5.7% | -15.0% | -26.8% |
| May 21 | Benchmark | Maintains | Buy → Buy | — | $189.48 | $186.48 | -1.6% | -9.8% | -1.1% | +2.7% | -8.8% | +1.2% |
| Apr 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $165.00 | $167.76 | +1.7% | -0.1% | -12.4% | -14.5% | +9.2% | -5.3% |
| Apr 28 | Stifel | Maintains | Buy → Buy | — | $164.40 | $172.44 | +4.9% | +0.4% | -0.1% | -12.4% | -14.5% | +9.2% |
| Apr 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $93.12 | $94.08 | +1.0% | -4.1% | -4.0% | +10.5% | +4.7% | +9.6% |
| Mar 12 | Piper Sandler | Downgrade | Overweight → Neutral | — | $100.44 | $131.40 | +30.8% | +13.5% | -24.2% | -14.9% | +19.7% | +1.4% |
| Jan 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $38.52 | $37.20 | -3.4% | -7.2% | +5.4% | +0.3% | -0.3% | -1.3% |
| Jan 2 | Piper Sandler | Maintains | Overweight → Overweight | — | $39.60 | $40.68 | +2.7% | -2.7% | -7.2% | +5.4% | +0.3% | -0.3% |
| Dec 19 | Roth Capital | Maintains | Buy → Buy | — | $31.56 | $34.20 | +8.4% | +30.8% | -4.1% | +12.7% | -0.8% | -3.8% |
| Mar 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $43.44 | $45.60 | +5.0% | +3.0% | -2.9% | +0.6% | +2.5% | -1.1% |
| Oct 18 | RBC Capital | Maintains | Outperform → Outperform | — | $74.88 | $76.32 | +1.9% | +1.3% | -1.1% | -0.3% | -5.0% | -2.2% |
| Jun 8 | Piper Sandler | Upgrade | Neutral → Overweight | — | $88.68 | $90.00 | +1.5% | +10.8% | -1.1% | +1.0% | +0.2% | -2.4% |
No insider trades available.
8-K
Inovio Pharmaceuticals, Inc. -- 8-K Filing
May 20
8-K · 2.02
!! High
Inovio Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
Inovio Pharmaceuticals disclosed its latest financial and operational results, though specific performance metrics require reviewing the attached press release for detailed earnings analysis.
May 13
8-K
Unknown — 8-K Filing
Inovio raised $16 million through a stock and warrant offering, diluting existing shareholders but providing cash runway for clinical development—investors should monitor whether this funding accelerates vaccine/immunotherapy programs enough to justify the dilution.
Apr 6
8-K
Unknown — 8-K Filing
This 8-K contains minimal substantive information—likely just standard corporate details—suggesting no major corporate events or material developments warrant investor attention at this time.
Apr 2
8-K
Unknown — 8-K Filing
Inovio's first FDA-reviewed BLA for INO-3107 under accelerated approval pathways signals potential near-term revenue catalyst, but investors should monitor approval timeline and commercial execution risk for this rare disease indication.
Mar 12
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Ultra-Small Company Fund | 173,000 | $301K | Mar 2026 |
| 2 | Small Cap Core Fund | 47,318 | $82K | Mar 2026 |
| 3 | Guggenheim Active Allocation Fund | 205 | $371 | Feb 2026 |
Valuation
Market Cap
$529.8M
Enterprise Value
$471.3M
P/E (TTM)
-0.66x
Forward P/E
—
PEG Ratio
0.18x
P/B
21.98x
P/S
—
P/FCF
-5.96x
EV/EBITDA
—
Shares Out
468.9M
Financials (TTM)
Revenue
$0
Net Income
-$84.9M
EBITDA
-$81.9M
Free Cash Flow
-$88.9M
Op Cash Flow
-$88.6M
EPS Basic
$-1.81
EPS Diluted
$-1.71
EPS Forward
$-1.15
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$74.3M
Total Liab.
$50.2M
Total Equity
$24.1M
Cash
$58.5M
LT Debt
$0
Book Value/Sh
$0.05
Debt/Equity
0.39x
Current Ratio
1.40
Quick Ratio
1.40
Returns & Growth
ROE
-352.5%
ROA
-114.3%
ROIC
-259.4%
Rev Growth YoY
-70.0%
EPS Growth YoY
+54.2%
Price Returns
2W
-3.7%
1M
+17.0%
3M
-27.6%
6M
-36.4%
12M
-34.5%
Technicals
52W High
$2.87
52W Low
$1.05
50d MA
$1.20
200d MA
$1.77
RSI (14)
35.70
ATR (14)
$0.06
Beta
1.70
Avg Volume
2.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.00
High
$6.00
Low
$6.00
Median
$6.00
Data updated apr 25, 2026 3:43pm
· Source: financialmodelingprep.com